Phase I Study of the Combination of Anlotinib With Gefitinib
Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the tolerability and toxicity of different
dose of Anlotinib puls Gefitinib in First-line Treatment of Advanced Gene Positive
Non-squamous Non-small Cell Lung Cancer , to provide a reference of dosage for Phase II
clinical trials